Individuals who meet the CDC’s clinical or epidemiologic criteria for testing can now be assessed using the LightMix Zika test. When used with compatible instruments, the test can analyze up to 96 plasma or serum samples, producing results within two and a half hours, according to Tech Times.
While the test has not earned FDA approval, the agency will permit the test’s use as long as Zika remains a national public health concern.
The agency previously provided emergency use authorizations for several other Zika diagnostic tests within the past few months in an effort to control the spread of the virus.
More articles on supply chain:
Mylan to introduce generic EpiPen at half the price
Ex-Turing CEO Martin Shkreli injects himself into EpiPen debate, defends price hike
Senators ask FDA for EpiPen alternatives: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
